Metoprolol ve hidroklorotiyazid etkileşimleri

Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. (Amilorid etiketi, Kutulu uyarı)

The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (Arsenik trioksit etiketi, Uyarılar ve önlemler)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (Benazepril ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

CONTRAINDICATIONS PROGLYCEM is contraindicated in patients with: Functional hypoglycemia Hypersensitivity to diazoxide, any of the excipients in PROGLYCEM, or other thiazides (Diazoksit etiketi, Kontrendikasyonlar)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide is contraindicated (see PRECAUTIONS, Drug-Drug Interactions ) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation. (Dofetilid etiketi, Kontrendikasyonlar)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (Droperidol etiketi, Kutulu uyarı)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalaprilat etiketi, Uyarılar)

…• serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions (7) , and Clinical Pharmacology (12.3)… (Eplerenon etiketi, Kontrendikasyonlar)

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Eptifibatid etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

…concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals Dosing Recommendations Doxycycline Take at least 1… (Ferrik sitrat etiketi, İlaç etkileşimleri)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (Flekainid etiketi, Kutulu uyarı)

Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (Follitropin etiketi, Uyarılar ve önlemler)

The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (Gentamisin etiketi, Kutulu uyarı)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Avoid diuretics or laxatives in patients with diarrhea. (İrinotekan etiketi, Uyarılar ve önlemler)

Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Kinapril etiketi, Uyarılar)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Klozapin etiketi, Kutulu uyarı)

Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Koriogonadotropin alfa etiketi, Uyarılar)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (Metirozin etiketi, Uyarılar)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Metolazon etiketi, Uyarılar)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (Nebivolol etiketi, İlaç etkileşimleri)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomisin etiketi, Kutulu uyarı)

The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (Potasyum sitrat etiketi, İlaç etkileşimleri)

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (Protamin etiketi, Kutulu uyarı)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (Repaglinid etiketi, İlaç etkileşimleri)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (Rivastigmin etiketi, İlaç etkileşimleri)

Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (Siklosporin etiketi, İlaç etkileşimleri)

Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Tadalafil etiketi, Uyarılar ve önlemler)

…Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (Tranilsipromin etiketi, İlaç etkileşimleri)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Alfuzosin etiketi, Uyarılar ve önlemler)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (Aliskiren etiketi, Uyarılar ve önlemler)

Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (Allopurinol etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (Amikasin etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Aripiprazol etiketi, İlaç etkileşimleri)

There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Armodafinil etiketi, Uyarılar ve önlemler)

Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Although β-blockers should be avoided in overt cardiac failure, acebutolol can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. (Asebutolol etiketi, Uyarılar)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Asenapin etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Atenolol etiketi, Uyarılar)

Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (Atenolol ve klortalidon etiketi, Uyarılar)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Atomoksetin etiketi, İlaç etkileşimleri)

• Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with azilsartan medoxomil. (Azilsartan etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Belladonna ve afyon etiketi, İlaç etkileşimleri)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Benazepril etiketi, Uyarılar ve önlemler)

Amphetamines may decrease the hypotensive effect of antihypertensives. (Benzfetamin etiketi, İlaç etkileşimleri)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Brekspiprazol etiketi, Uyarılar ve önlemler)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Brimonidin etiketi, İlaç etkileşimleri)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Bromfeniramin, psödoefedrin ve dekstrometorfan etiketi, İlaç etkileşimleri)

Use caution in patients taking antihypertensive medications. (Bromokriptin etiketi, Uyarılar ve önlemler)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (Bupivakain etiketi, Uyarılar ve önlemler)

Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Butalbital, parasetamol, kafein ve kodein etiketi, İlaç etkileşimleri)

Tiyazid diüretikler kalsiyum atılımını azaltır; D vitamini ve kalsiyum takviyeleriyle birlikte bu durum, özellikle yaşlı yetişkinlerde hiperkalsemiye yol açabilir. (NIH Office of Dietary Supplements, Vitamin D)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Dekslansoprazol etiketi, Uyarılar ve önlemler)

• Antihypertensive Drugs: Monitor blood pressure. (Deksmetilfenidat etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (Desipramin etiketi, Uyarılar)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (Desvenlafaksin etiketi, Uyarılar ve önlemler)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Dietilpropion etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (Dihidroergotamin etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Dokserkalsiferol etiketi, Uyarılar ve önlemler)

Drug Interactions with Metoprolol Catecholamine Depleting Drugs: The concomitant use of catecholamine-depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) with beta adrenergic blockers may have an additive affect and increase the risk of hypotension or bradycardia CYP2D6 Inhibitors: Drugs that are strong inhibitors of CYP2D6 such as quinidine,… (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Give a low dose of beta-blockers initially, and increase only after ECG verification of good tolerability [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Dronedaron etiketi, İlaç etkileşimleri)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalapril etiketi, Uyarılar ve önlemler)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Epoetin alfa etiketi, Uyarılar ve önlemler)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (Ergotamin ve kafein etiketi, İlaç etkileşimleri)

Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (Esmolol etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Esomeprazol etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Essitalopram etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

…treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (Fentanil etiketi, Uyarılar ve önlemler)

Concomitant administration of hydrochlorothiazide alone with topiramate alone has been shown to increase the C max and AUC of topiramate by 27% and 29%, respectively. (Fentermin ve topiramat etiketi, İlaç etkileşimleri)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (Fludrokortizon etiketi, İlaç etkileşimleri)

Hydrochlorothiazide In a pharmacokinetic interaction study, coadministration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentrations of fluconazole by 40%. (Flukonazol etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Propranolol or metoprolol : Reduce dose if coadministered and titrate more cautiously ( 7.3 ). (Fluvoksamin etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs. (Fosinopril etiketi, İlaç etkileşimleri)

The thiazide component of fosinopril sodium and hydrochlorothiazide may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. (Fosinopril ve hidroklorotiyazid etiketi, Uyarılar)

When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (Foskarnet etiketi, İlaç etkileşimleri)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of metoprolol. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Haloperidol etiketi, İlaç etkileşimleri)

Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon etiketi, İlaç etkileşimleri)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve homatropin etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve klorfeniramin etiketi, İlaç etkileşimleri)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon ve parasetamol etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidromorfon etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (İloperidon etiketi, Uyarılar ve önlemler)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (İmipramin etiketi, Uyarılar)

Drug Interactions Other Antihypertensives: Indapamide may add to or potentiate the action of other antihypertensive drugs. (İndapamid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with AVAPRO. (İrbesartan etiketi, Uyarılar ve önlemler)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (İvabradin etiketi, İlaç etkileşimleri)

Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects. (İzofluran etiketi, İlaç etkileşimleri)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. (Kalsitriol etiketi, İlaç etkileşimleri)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Kalsiyum klorür etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Kandesartan etiketi, Uyarılar ve önlemler)

Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (Kaptopril etiketi, Uyarılar)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (Karbamazepin etiketi, Uyarılar ve önlemler)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Karbidopa etiketi, İlaç etkileşimleri)

Antihypertensive drugs: May cause symptomatic postural hypotension. (Karbidopa ve levodopa etiketi, İlaç etkileşimleri)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Karbidopa, levodopa ve entakapon etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Kariprazin etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ketiapin etiketi, Uyarılar ve önlemler)

Antivirals indinavir, maraviroc, saquinavir Beta Blockers nadolol Calcium Channel Blockers felodipine, nisoldipine other dihydropyridines, verapamil Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. (Ketokonazol etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

The thiazide component of quinapril and hydrochlorothiazide tablets may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic- blocking drugs. (Kinapril ve hidroklorotiyazid etiketi, Uyarılar)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Although clinical drug interaction studies have not been performed, antimalarial doses (greater than or equal to 600 mg) of quinine may inhibit the metabolism of other drugs that are CYP2D6 substrates (e.g., flecainide, debrisoquine, dextromethorphan, metoprolol, paroxetine ). (Kinin etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Consider use of diuretics and/or albumin. (Klofarabin etiketi, Uyarılar ve önlemler)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (Klorotiyazid etiketi, Uyarılar)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Kodein etiketi, İlaç etkileşimleri)

Cholestyramine and colestipol: Reduced absorption of thiazides. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Cholestyramine and colestipol: Reduced absorption of thiazides. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (Lakozamid etiketi, Uyarılar ve önlemler)

Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Lansoprazol etiketi, Uyarılar ve önlemler)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Ledipasvir ve sofosbuvir etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Levomilnasipran etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Levorfanol etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Drug or Drug Class Effect Beta-adrenergic antagonists e.g., Propranolol > 160 mg/day) In patients treated with large doses of propranolol (> 160 mg/day), T 3 and T 4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. (Levotiroksin etiketi, İlaç etkileşimleri)

Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Lisinopril etiketi, Uyarılar ve önlemler)

When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed (see DOSAGE AND ADMINISTRATION ). (Lisinopril ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Lithium: Risk of lithium toxicity. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Drug or Drug Class Effect Beta-adrenergic antagonists (e.g., Propranolol >160 mg/day) In patients treated with large doses of propranolol (>160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. (Liyotironin etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (Losartan etiketi, Uyarılar ve önlemler)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Lumateperon etiketi, Uyarılar ve önlemler)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Lurasidon etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (Meflokin etiketi, İlaç etkileşimleri)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (Mekamilamin etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (Metadon etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (Metilergometrin etiketi, İlaç etkileşimleri)

Antihypertensive Drugs: Monitor blood pressure. (Metilfenidat etiketi, İlaç etkileşimleri)

…(oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. (Metimazol etiketi, İlaç etkileşimleri)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Tartrate Tablets [see Dosage and Administration (2) ]. (Metoprolol etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (Milnasipran etiketi, Uyarılar ve önlemler)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (Mirtazapin etiketi, Uyarılar ve önlemler)

However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (Modafinil etiketi, Uyarılar ve önlemler)

Symptomatic hypotension is most likely to occur in patients who have been salt- and volume- depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Moeksipril etiketi, Uyarılar)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Morfin etiketi, İlaç etkileşimleri)

Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (Motiksafortid etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (Nadolol etiketi, Uyarılar)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Nalbufin etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Niasin etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antihypertensives: Possible additive hypotensive effects. (Nitrogliserin etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon ve parasetamol etiketi, İlaç etkileşimleri)

Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. (Oksimetazolin etiketi, İlaç etkileşimleri)

Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksimorfon etiketi, İlaç etkileşimleri)

Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Oktreotid etiketi, Uyarılar ve önlemler)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Olanzapin etiketi, Uyarılar ve önlemler)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oliseridin etiketi, İlaç etkileşimleri)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. (Olmesartan etiketi, Uyarılar ve önlemler)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol ve sodyum bikarbonat etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Paliperidon etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Pantoprazol etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Parasetamol ve kodein etiketi, İlaç etkileşimleri)

The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Parikalsitol etiketi, Uyarılar ve önlemler)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (Pasireotid etiketi, Uyarılar ve önlemler)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib etiketi, Uyarılar ve önlemler)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Pentazosin ve nalokson etiketi, İlaç etkileşimleri)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Pentoksifilin etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been volume or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting [see Dosage and Administration (2.1) ] . (Perindopril etiketi, Uyarılar ve önlemler)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Petidin etiketi, İlaç etkileşimleri)

Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (Pilokarpin etiketi, İlaç etkileşimleri)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, pindolol tablets can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (Pindolol etiketi, Uyarılar)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (Piridostigmin etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (Ponesimod etiketi, Uyarılar ve önlemler)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Potasyum iyodür etiketi, İlaç etkileşimleri)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (Prazosin etiketi, Uyarılar)

Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Proklorperazin etiketi, Önlemler)

Diuretics : Codeine may reduce the efficacy of diuretics. (Prometazin ve kodein etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Beta-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. (Propiltiourasil etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Rabeprazol etiketi, Uyarılar ve önlemler)

Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (Ramipril etiketi, Uyarılar ve önlemler)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Decrease exposure Beta-blockers Metoprolol Decrease exposure Propranolol Decrease exposure Benzodiazepines Diazepam , Administered with rifampin 1200 mg daily Decrease exposure Benzodiazepine-related drugs Zopiclone Decrease AUC by 82% Zolpidem Decrease AUC by 73% Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as… (Rifampisin etiketi, İlaç etkileşimleri)

…Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (Rifapentin etiketi, İlaç etkileşimleri)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Riosiguat etiketi, Uyarılar ve önlemler)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Risperidon etiketi, Uyarılar ve önlemler)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Nadolol/Metoprolol : In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). (Rizatriptan etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (Ropivakain etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. (Sakubitril ve valsartan etiketi, Uyarılar ve önlemler)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (Sefepim etiketi, İlaç etkileşimleri)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (Seftazidim etiketi, İlaç etkileşimleri)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sertralin etiketi, Uyarılar ve önlemler)

DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (Sevimelin etiketi, İlaç etkileşimleri)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Siklobenzaprin etiketi, İlaç etkileşimleri)

…inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity… (Siklofosfamid etiketi, İlaç etkileşimleri)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Sildenafil etiketi, Uyarılar ve önlemler)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Silodosin etiketi, Uyarılar ve önlemler)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sitalopram etiketi, Uyarılar ve önlemler)

Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (Sodyum zirkonyum siklosilikat etiketi, Uyarılar ve önlemler)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Sofosbuvir ve velpatasvir etiketi, Uyarılar ve önlemler)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (Sotalol etiketi, Uyarılar ve önlemler)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of metoprolol. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of metoprolol. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib etiketi, Uyarılar ve önlemler)

Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (Süksinilkolin etiketi, Uyarılar ve önlemler)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (Takrolimus etiketi, Uyarılar ve önlemler)

…use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tapentadol etiketi, İlaç etkileşimleri)

Beta-adrenergic Receptor Antagonists (e.g., acebutolol, metoprolol) Beta-adrenergic receptor antagonists have been shown to reduce the production of melatonin via specific inhibition of beta-1 adrenergic receptors. (Tasimelteon etiketi, İlaç etkileşimleri)

Hypotension In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan tablets. (Telmisartan etiketi, Uyarılar ve önlemler)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (Terazosin etiketi, Uyarılar ve önlemler)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Testosteron etiketi, Uyarılar ve önlemler)

Drug Interactions with Metoprolol Catecholamine Depleting Drugs: The concomitant use of catecholamine-depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) with beta adrenergic blockers may have an additive affect and increase the risk of hypotension or bradycardia CYP2D6 Inhibitors: Drugs that are strong inhibitors of CYP2D6 such as quinidine,… (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Antidiabetic drugs: Dosage adjustment may be required. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (Tobramisin etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects of diuretics. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (Tolvaptan etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide (HCTZ) Topiramate C max and AUC increased when HCTZ was added to immediate-release topiramate. (Topiramat etiketi, İlaç etkileşimleri)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of metoprolol. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (Toremifen etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol ve parasetamol etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been salt- or volume-depleted as a result of prolonged treatment with diuretics, dietary salt restriction, dialysis, diarrhea, or vomiting. (Trandolapril etiketi, Uyarılar)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Trazodon etiketi, Uyarılar ve önlemler)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of metoprolol. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of metoprolol. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Trifluoperazin etiketi, Önlemler)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Drug Interactions with Metoprolol Catecholamine Depleting Drugs: The concomitant use of catecholamine-depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) with beta adrenergic blockers may have an additive affect and increase the risk of hypotension or bradycardia CYP2D6 Inhibitors: Drugs that are strong inhibitors of CYP2D6 such as quinidine,… (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. (Valsartan etiketi, Uyarılar ve önlemler)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Vardenafil etiketi, İlaç etkileşimleri)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (Venlafaksin etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (Vilazodon etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (Vortioksetin etiketi, Uyarılar ve önlemler)

Zileuton increases propranolol levels and beta-blocker activity. (Zileuton etiketi, İlaç etkileşimleri)

Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (Ziprasidon etiketi, Uyarılar ve önlemler)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (Zoledronik asit etiketi, Uyarılar ve önlemler)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (Adenozin etiketi, İlaç etkileşimleri)

Coadministration of 1 Dyazide (triamterene/hydrochlorothiazide) resulted in a higher plasma amantadine hydrochloride concentration in a 61-year old man receiving amantadine hydrochloride 100 mg TID for Parkinson's disease. (Amantadin etiketi, İlaç etkileşimleri)

Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (Ambrisentan etiketi, Uyarılar ve önlemler)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (Bosentan etiketi, Uyarılar ve önlemler)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Butorfanol etiketi, Uyarılar)

Tiyazid diüretikler uzun süreli kullanımda idrarla çinko kaybını artırır. (NIH Office of Dietary Supplements, Zinc)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). (Dekstroamfetamin etiketi, İlaç etkileşimleri)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Desogestrel ve etinilestradiol etiketi, Uyarılar)

Pheochromocytoma: First initiate therapy with an alpha blocker. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Dosetaksel etiketi, Uyarılar ve önlemler)

Pheochromocytoma: First initiate therapy with an alpha blocker. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Efedrin etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

In addition to discontinuation of the drug, diuretic therapy may be required. (Esterifiye östrojenler ve metiltestosteron etiketi, Uyarılar)

In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

Pheochromocytoma: First initiate therapy with an alpha blocker. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Pheochromocytoma: First initiate therapy with an alpha blocker. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

…PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (Finasterid etiketi, İlaç etkileşimleri)

Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (Fingolimod etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (İkatibant etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Tiyazid diüretikler kalsiyum atılımını azaltır; bu nedenle yüksek kalsiyum alımı kandaki kalsiyumu yükseltebilir. (NIH Office of Dietary Supplements, Calcium)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Kalsiyum glukonat etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (Kortikotropin etiketi, İlaç etkileşimleri)

Pheochromocytoma: First initiate therapy with an alpha blocker. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Abrupt withdrawal in thyrotoxicosis might precipitate a thyroid storm. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Kıvrım (loop) diüretiklerinin ve tiyazid diüretiklerin uzun süreli kullanımı idrarla magnezyum kaybını artırır. (NIH Office of Dietary Supplements, Magnesium)

Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (Masitentan etiketi, Uyarılar ve önlemler)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (Meksiletin etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Metilprednizolon etiketi, İlaç etkileşimleri)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (Milrinon etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

The antihypertensive action of guanethidine and similar agents may be blocked. (Nortriptilin etiketi, Uyarılar)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (Perfenazin etiketi, İlaç etkileşimleri)

Kıvrım (loop) diüretikleri ve tiyazid diüretikler potasyum kaybını artırır; bazen bunlarla birlikte takviye reçete edilir. (NIH Office of Dietary Supplements, Potassium)

Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizolon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Protriptilin etiketi, Uyarılar)

Pheochromocytoma: First initiate therapy with an alpha blocker. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Abrupt withdrawal in thyrotoxicosis might precipitate a thyroid storm. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents ( i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Triamsinolon etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (İbutilid etiketi, İlaç etkileşimleri)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronat etiketi, İlaç etkileşimleri)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (Ropinirol etiketi, İlaç etkileşimleri)

Table 5: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Dosing Recommendations Ciprofloxacin Take at least 2 hours before… (Sevelamer etiketi, İlaç etkileşimleri)